Navigation Links
Catabasis Initiates Phase 1 Trial of CAT-2003 for Treatment of Severe Hypertriglyceridemia
Date:3/26/2013

CAMBRIDGE, Mass., March 26, 2013 /PRNewswire/ -- Catabasis Pharmaceuticals Inc., today announced the initiation of a Phase 1 study to investigate the safety and tolerability of CAT-2003 in healthy volunteers and in adults with mildly elevated lipids. CAT-2003 is a conjugate of niacin and eicosapentaenoic acid (EPA), an omega-3 fatty acid, covalently linked using the company's proprietary SMART Linker technology to create a new chemical entity and is being developed for patients with severe hypertriglyceridemia.

"Advancing CAT-2003 into the clinic is another important milestone for Catabasis after recently announcing positive Phase 1 data for CAT-1004 that validated our SMART Linker platform," said Michael Jirousek , Ph.D., chief scientific officer of Catabasis. "In preclinical animal models, CAT-2003 produced robust triglyceride and low density lipoprotein (LDL) cholesterol lowering, and synergistic reductions in LDL cholesterol when CAT-2003 was combined with a statin."

This randomized, double-blind, placebo-controlled Phase 1 study will be conducted in two parts. In the first part, healthy adults will receive a single ascending dose of CAT-2003 or placebo. In the second part, healthy adults or patients with mildly elevated lipids will receive CAT-2003 or placebo daily for 14 days. The study will evaluate safety, tolerability and pharmacokinetics.  Triglycerides, LDL cholesterol and biomarkers related to the mechanism of action of CAT-2003 will also be assessed. Data is expected in the second quarter of 2013.

For more information on this trial see clinicaltrials.gov.

About CAT-2003CAT-2003 is a new chemical entity that is a conjugate of the B vitamin niacin and eicosapentaenoic acid (EPA), an omega-3 fatty acid, linked using the company's proprietary SMART Linker technology. It is being investigated for the treatment of severe hypertriglyceridemia. In preclinical models of severe hypertriglyceridemia, a significant and dose-dependent reduction in plasma triglycerides was observed with CAT-2003, while a simple combination of niacin and omega-3 had only a marginal effect. In preclinical models of dyslipidemia, CAT-2003 dramatically reduced LDL cholesterol.  In combination with a statin, CAT-2003 synergistically lowered LDL cholesterol.  Because CAT-2003 is not activated until it is delivered to the target cell, CAT-2003 is not expected to activate the receptor that causes "niacin flush," a side effect characterized by blushing of the skin and a sensation of warmth resulting from blood vessel dilation; this effect can reduce patient compliance.

About HypertriglyceridemiaSevere hypertriglyceridemia refers to a condition involving levels of triglycerides equal to or above 500 mg/dL. Severe hypertriglyceridemia is associated with markedly increased risk for cardiovascular disease and pancreatitis, and recent studies have demonstrated that elevated triglyceride levels can be regarded as an independent risk factor for cardiovascular events such as myocardial infarction, ischemic heart disease and ischemic stroke.  The prevalence of hypertriglyceridemia is rapidly increasing in the United States and throughout the world.  It is estimated that over four million patients have severe hypertriglyceridemia in the United States. The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol recommends that the first priority for the management of severe hypertriglyceridemia be triglyceride reduction to decrease the risk of pancreatitis. Current treatments include adhering to a low-fat, low-carbohydrate diet, exercise and alcohol abstinence. Medical therapies can include statins to normalize other lipid parameters, fibrates and omega-3 fatty acids.

About CatabasisCatabasis is a clinical-stage company dedicated to the discovery and development of innovative, effective and safe medicines to treat inflammatory and metabolic diseases. The company's drug development programs are rooted in the principles of pathway pharmacology, the treatment of diseases by simultaneously modulating more than one target in a disease pathway. Using its proprietary SMART Linker technology, the company conjugates two drugs that act on different components of a disease pathway to produce new chemical entities with significantly enhanced efficacy and an improved safety and tolerability profile. The company has assembled a team of passionate and experienced scientists who are committed to improving the lives of patients. The company was founded in 2008 and is headquartered in Cambridge, Mass.

Please visit www.catabasis.com for more information.Media ContactsCorporate ContactTony Russo, Ph.D.Amy LynchMatt Middleman, M.D.Catabasis Pharmaceuticals, Inc.Russo Partners T: (617)-349-1971T: 212-845-425alynch@catabasis.comT: 212-845-4272tony.russo@russopartnersllc.commatt.middleman@russopartnersllc.com
'/>"/>

SOURCE Catabasis Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Alliqua Initiates Life-Cycle Management Plan to Expand Wound Care Portfolio for Use in Broader Wound Indications
2. Lithera Initiates Phase 2b Clinical Trial of LIPO-202 Targeting Aesthetic Reduction of Subcutaneous Abdominal Fat
3. Isis Pharmaceuticals Initiates Phase 2 Study Of ISIS-CRP Rx In Patients With Atrial Fibrillation
4. NxStage Initiates 2013 Call to Action Campaign with Launch of Hemodialysis At Home: A Better Way For a Better Life
5. Coyote Pharmaceuticals Initiates GMP Manufacturing Process for CNS-102 Following Successful Pre-IND Meeting
6. Nanomix Initiates Clinical Testing of Point of Care IVD Cardiac Panel
7. ADVENTRX Initiates Pivotal Phase 3 Study of ANX-188
8. uniQure Initiates Phase I in Acute Intermittent Porphyria
9. Fate Therapeutics Initiates Phase 2 Clinical Study of ProHema for the Treatment of Hematologic Malignancies
10. The Acute Liver Failure Study Group Initiates Phase 2a Study of OCR-002 for Treatment of Acute Liver Failure after Acetaminophen Overdose
11. Isis Pharmaceuticals Initiates Phase 1b/2a Study Of ISIS-SMNRx In Patients With Spinal Muscular Atrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... Sept. 18, 2017 EpiVax, Inc. ... bioinformatics and immune engineering, today announced a ... A (H7N9) vaccine. ... seasonal influenza and presents a challenge for ... exposure to be effective. Using state-of-the-art bioinformatics and ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , ... supply chains, has published the first annual edition of its Global CSR ... than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed ... ... & Performance Index ...
(Date:9/12/2017)...  ValGenesis Inc., the global leader in Enterprise ... announce the appointment of Dr. Ajaz Hussain ... Directors and Chairman of Advisory Board beginning September ... to manage their entire validation lifecycle process electronically ... process. Furthermore, ValGenesis VLMS enables rigorous compliance, helps ...
Breaking Medicine Technology:
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... “Finn Mouseson”: ... take precedence in an average life. This mouse sets out on a journey that ... heart. “Finn Mouseson” is the creation of newly published author and illustrator, Melody Gersonde-Mickelson, ...
(Date:9/20/2017)... ... ... “The Financial Favor of God; Second Edition”: a personal and exquisite recipe ... creation of published author, Brooks Rathell. , “We typically hear about the favor of ... financial favor of God. Not only does it exist, but it is meant for ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola Group, ... marketing leader, Denise Flannery, to its strategic advisory and client development team. ... will work with clients across different industries to develop and implement market-justified strategies, ...
(Date:9/19/2017)... ... 2017 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Swirl: A Wine Tasting Event series on Thursday, October 26, 2017. Hosted at ...
(Date:9/19/2017)... MD (PRWEB) , ... September 19, 2017 , ... ... the Society of Professional Benefit Administrators (SPBA) hosted “Expanding Your Success” ... for SPBA Members as it focused on best practices for third party administrators ...
Breaking Medicine News(10 mins):